The serum concentration of sST2, the soluble form of the receptor for both IL-33 and IL-1, has been shown to be elevated in patients with metastatic BC, and knockdown of the sST2 decreases ErbB2-induced cell motility in two different cell lines (23). Here, ERBB2 is linked to breast cancer.